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Abstract
Background: Europe was certified to be polio-free in 2002 by the WHO. However, wild polioviruses remain
endemic in India, Pakistan, Afghanistan, and Nigeria, occasionally causing polio outbreaks, as in Tajikistan in 2010.
Therefore, effective surveillance measures and vaccination campaigns remain important. To determine the
poliovirus immune status of a German study population, we retrospectively evaluated the seroprevalence of
neutralizing antibodies (NA) to the poliovirus types 1, 2 and 3 (PV1, 2, 3) in serum samples collected from 1,632
patients admitted the University Hospital of Frankfurt am Main, Germany, in 2001, 2005 and 2010.
Methods: Testing was done by using a standardized microneutralization assay.
Results: Level of immunity to PV1 ranged between 84.2% (95%CI: 80.3-87.5), 90.4% (88.3-92.3) and 87.5% (85.4-88.8)
in 2001, 2005 and 2010. For PV2, we found 90.8% (87.5-90.6), 91.3% (89.3-93.1) and 89.8% (88.7-90.9), in the same
period. Seroprevalence to PV3 was 76.6% (72.2-80.6), 69.8% (66.6-72.8) and 72.9% (67.8-77.5) in 2001 and 2005 and
2010, respectively. In 2005 and 2010 significant lower levels of immunity to PV3 in comparison to PV1 and 2 were
observed. Since 2001, immunity to PV3 is gradually, but not significantly decreasing.
Conclusion: Immunity to PV3 is insufficient in our cohort. Due to increasing globalization and worldwide tourism,
the danger of polio-outbreaks is not averted - even not in developed countries, such as Germany. Therefore,
vaccination remains necessary.
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Background
Poliovirus, the etiologic agent of paralytic poliomyelitis
(hereinafter referred to as polio), is a positive-sensed sin-
gle-stranded RNA virus, which belongs to the genus Enter-
ovirus. Enteroviruses in turn are a species of small,
pathogenic, icosahedral viruses belonging to the family
Picornaviridae. Polioviruses are subdivided in three immu-
nologically different serotypes: poliovirus type 1, 2 and 3
(hereinafter referred to as PV1, 2, 3). Since 1960, polio has
been controlled by the use of live oral polio vaccine (OPV)
or inactivated polio vaccine (IPV). The latter poses no risk
of vaccine-associated paralytic polio and has been used in
Germany since 1998 [1,2]. Polio usually affects children
under the age of 5 years: paralytic polio has been seen in
one of 200 cases, fatal cases are seen in about 5-10% of
paralytic polio in developing countries [3]. The number of
polio cases has been reduced by > 99%, from an estimated
number of 350,000 cases worldwide in 1988 [4] to 1,606
cases in 2009 [4] and 1,294 cases in 2010 [5]. While Ger-
many was deemed to be polio-free by WHO on June, 21
st
in 2002 [6], circulating wild polioviruses remain endemic
in four major locations: Nigeria, Pakistan, Afghanistan and
India [4,7,8]. The occurrence of polio outbreaks, such
those reported in Tajikistan, Turkmenistan and Kazakh-
stan in 2010 [9,10] or Angola in 2007/2008 [11] underlines
the necessity of vaccination campaigns for polio preven-
tion. Epidemiological surveillance is also crucial to docu-
ment polio-absence in polio-free countries. Between 1997
and 2010 Germany has taken part in the acute flaccid
paralysis (AFP)-program, which was initiated to exclude a
PV-infection by a two-time stool investigation in cases of
AFP in children younger than 15 years. Because of low
participation rates an alternative surveillance-program was
initiated in Germany by the National Commission for
Polio-Eradication in the Federal Republic of Germany
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tut (RKI), Berlin, Germany, in 2005. It is the so called
Enterovirus-Surveillance, which bases on laboratory diag-
nostic clarification of viral meningitis or encephalitis by
stool or cerebrospinal fluid (CSF). By Enterovirus-Surveil-
lance Germany fulfils the obligation to prove to be and
remain polio-free, as required by WHO. Up to date, no
polio-caused AFP case has been detected in Germany [12].
The objective of our study was to describe the immunity
status to PV1, 2, 3 of a German urban cohort 13 years
after introduction of IPV and 9 years after elimination of
polio in Germany. Therefore, we retrospectively evaluated
the seroprevalence of neutralizing antibodies (NA) to PV1,
2, 3 using microneutralization assay (MNA) in 1,632 routi-
nely collected serum samples in the university-hospital of
Frankfurt am Main, Germany. Furthermore, we quantita-
tively analyzed and evaluated the level of immunity to
PV1, 2, 3 by titres on average.
Methods
In the years 2001, 2005 and 2010 we tested 411, 878 and
343 serum samples, respectively, for NA to PV1, 2, 3.
The serum samples were obtained from patients
admitted to the University Hospital of Frankfurt am
Main, Germany (FRA).
As we conducted an unlinked anonymous retrospective
study, patients’ data regarding age and sex were available.
However, data concerning nationality, residence or con-
comitant diseases were not available.
The samples were routinely screened for NA against
PV1, 2, 3 by MNA. MNA and controls are performed by
an in-house procedure according to WHO guidelines [13]
using vaccine-PV-strains. Currently, trivalent IPVs are
mainly produced using the poliovirus strains Mahoney
(PV1), MEF-1 (PV2), and Saukett (PV3), grown in Vero
cell line [14,15] The strains were obtained from the Ger-
man reference laboratory for poliomyelitis and entero-
viruses at the Robert Koch Institut, Berlin. The MNA was
performed as previously described [16]. Briefly: Sera were
inactivated at 56°C for 30 min before use, diluted two-fold
from 1:10 to 1:1280 and then incubated for 1 h at 37°C (in
aC O 2 incubator) with 100 tissue culture infective dose50
(TCID50) of challenge virus (either PV1, 2 or 3). After the
incubation period 50 μl of the serum-virus suspension was
added to 50 μl of Vero cells suspension (African green
monkey kidney, ATCC CCL-81). Cell controls and a refer-
ence serum of known PV1,2,3 neutralizing activity was
included in each test to examine reproducibility of results.
Each test serum was investigated in triplicate. After incu-
bation for 5-7 days, the highest dilution of serum that pre-
vents the development of virus induced cytopathogenic
effects (CPE) was recorded. The NA titre corresponded to
the reciprocal of this dilution. A serum sample was consid-
ered positive, if antibodies were present at a dilution 1: ≥
10 of the serum specimen.
Statistical analysis was done by using the 95% confi-
d e n c ei n t e r v a l( 9 5 % C I )w i t has i g n i f i c a n c el e v e lo fp <
0.05, Chi-Square test or the Fisher’s exact test in the case
of low sample numbers by using the program BIAS for
Windows 8.3 (Epsilon Verlag, Hochheim Darmstadt
2007). Differences were regarded significant with an
error probability of p < 0.05. The Kruskal-Wallis test was
used for analyzing the association of seroprevalence and
age. Results are presented in modification of age groups
defined by WHO. Modification in this context means
consolidation of 2 or 3 age groups within a single because
of low sample numbers in the age group recommended
by WHO. We furthermore used three, previously defined
[16] NA titre ranges and used them to quantify the level
of immunity to PV1, 2, 3. Thus, low, medium and high
immunity is given for titre ranges between 1:10-1:20 and
1:40-1:160 and 1:320-1:1280, respectively.
Results
A non-age-specific, overall evaluation of PV1, 2, 3-NA is
s h o w ni nF i g u r e1 .S e r o p r e v a l e n c e( w i t h9 5 % C Ii n
brackets) of NA to PV1 amounts 84.2% (80.3-87.5),
90.4% (88.3-92.3) and 87.5% (85.4-88.8) in 2001, 2005
and 2010, respectively. Highest levels of seropositivity
were detectable for PV2 with 90.8% (87.5-90.6), 91.3%
(89.3-93.1) and 89.8% (88.7-90.9) in 2001, 2005 and
2010, respectively. Lowest seroprevalences were
observed for PV3: values ranged between 76.6% (72.2-
80.6), 69.8% (66.6-72.8) and 72.9% (67.8-77.5) in 2001
and 2005 and 2010, respectively.
In Figure 2 the age-specific seroprevalence of NA to
PV1, 2, 3 is illustrated. In the age group of 15-29 years
highest level of seropositivity to PV1 (all values in [%]:
90.2; 95%CI: 82.7-95.2) and PV2 (93.1; 86.3-97.2) were
recorded. Highest level of seroprevalence to PV3 (78.8;
66.9-87.8) was detected in the group aged > 30 years. In
comparison to PV1 and PV2, all the age groups show a
lower level of seroprevalence of anti-PV3. In the group
aged 15-29 years a significant lower seroprevalence to PV3
(72.5; 62.8-80.9) than to PV1 (90.2; 82.7-95.2) and PV2
(93.1; 86.3-97.2) was detectable (p < 0.05).
A qualitative analysis of the NA titres using three levels
of immunity (low [1:10-1:20], medium [1:40-1:160], high
[1: > 320]) was used to assess the level of immunity to
PV1, 2, 3. No immunity is given for titres lower than 1:10.
Figure 3 illustrates the distribution to these immunity-
levels. It shows a decreasing number of PV3-"high immu-
nity"-sera from 2001 to 2005 and 2010 while the percen-
tage of samples with “no immunity” is significantly
increased over years (p = 0.008; see Figure 4).
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Type of poliovirus and age group (years) 
Figure 2 Age-specific seroprevalence of NA to PV1, PV2, PV3 in 2010 (95%CIs are represented by black lines).
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Figure 4 Lack of immunity to PV3 (95% CI are represented by black lines).
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From the epidemiological point of view, eradication of
polio is a matter of urgency. The spread of wild polio-
viruses from endemic areas to polio-free countries
remains a potential risk, as vaccination coverage rates
can decrease, and vaccine-induced immunity can wane.
For this reasons, vaccination campaigns and epidemiolo-
gical surveillance are absolutely necessary to maintain
and verify polio-absence in polio-free countries.
In our study population, we found a distinctive gap for
PV3. This gap has previously been described by Weber
et al. [16], Wicker et al. [17], Diedrich et al. in [18,19],
Franck et al. [20], but we found a further increase of
this hiatus. In fact, also in our study the immunity level
to PV3 is the lowest among all types of poliovirus
[16-26]. This result can be explained by a reduced anti-
genicity immunogenicity of PV3 when compared to PV1
and PV2 [26]. This should be an aspect of interest in
future vaccine development. An interesting aspect is
that lowest seroprevalences of antibodies to PV1 - 3
were observed in the group aged 1-14 years (Figure 2).
This phenomenon may be coherent with the implemen-
tation of IPV in Germany in 1998 [1,2]. When OPV was
used, no such gap was observed [21].
Not only from this point of view but also in consid-
eration of globalisation and worldwide tourism, polio
remains an important theme: due to travel by air,
importation of PV from endemic areas can occur within
hours by air traffic. In Germany, 10-20% of inhabitants
are immigrants [27,28], and may frequently invite or
visit their relatives abroad. Consequently the risk of PV-
import to Germany from endemic countries is present,
and necessitates maintenance of an immune population
until polio is eradicated globally.
Available data on immunological status to PV from
other countries should be compared with caution, since
determination of neutralizing antibodies is a biological
assay with big deviations [28].
In Portugal 91.6%, 94.2% and 75% of the tested persons
had shown protective antibodies to PV 1,2,3, respectively,
in 2002 [22]. Immigrants from less developed countries
in North-East Italy were seropositive to PV 1, 2, 3 in
98.3%, 99.6% and 95.9%, respectively [23]. Furthermore
in Israel, 18 year-old soldiers recruited to the Israel
Defence Forces tested for antibodies to PV1, 2, 3 were
found to be protected in 98.7%, 99.6% and 96.4%, respec-
tively [24]. In Jilin Region, China, 95%, 94.6% and 92.3%,
had positive test results of NA against Polio type 1,2,3,
respectively [25]. In comparison to our PV-seropreva-
lences (and also to former studies from Germany
[16,18-21]) the results mentioned above are markedly
higher. The reason for this phenomenon is unclear. In
which way it is influenced by the way of titration,
definition of the cut-off titre and counting of dilution
(final dilution vs. serum dilution) remains unclear.
In a population of women attending antenatal in
southern India, nearly 50% had shown no immunity
(titres 1: < 8) against polio, with the lowest levels for
PV3 and 1 [29]. Nepal, a country three of four endemic
countries, also shows hard effort in the fight against
polio. However, while high acceptance of vaccination-
programs is documented [30], seroprevalence data are
lacking. Seroprevalence surveys are necessary to identify
population-categories at risk to be susceptible for polio,
and to target specific vaccination activities to protect
these groups. The availability of PV 1 and PV 3 mono-
valent vaccines vaccine could provide the global polio-
myelitis eradication initiative with additional vaccine
options [31], even though it could complicate decision
making on vaccination policies.
Optimization of immunity to PV3 is a matter of urgency.
As mentioned above and shown in Figure 1, 2, 3, 4, sero-
prevalence of NA to PV3 has been decreasing in Germany
for several years. Therefore, continuing vaccination cam-
paigns are as important as monitoring the population’s
immunity to sustain the present polio-free situation.
Conclusions
Despite intensive efforts in the fight against polio, it
remains endemic in India, Pakistan, Afghanistan and
Nigeria. Therefore, vaccination campaigns are as impor-
tant as maintaining surveillance to monitor enteroviral
events - including those countries, which are deemed to
be polio-free by WHO. Even if the European countries
are known to be polio-free the danger has not been
completely averted: we observed a distinctive gap in
immunity to PV3 in all age-groups and furthermore a
decreasing immunity to PV, overall. Thus, we learn that
vaccination against polio is absolutely necessary further
on to preserve our present polio-free situation.
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